Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial.

ABSTRACT:

Objective

We evaluated whether ivermectin combined with doxycycline reduced the clinical recovery time in adults with COVID-19 infection.

Methods

This was a randomized, blinded, placebo-controlled trial in patients with mild-to-moderate COVID-19 symptoms randomly assigned to treatment (n = 200) and placebo (n = 200) groups. The primary outcome was duration from treatment to clinical recovery. Secondary outcomes were disease progression and persistent COVID-19 positivity by RT-PCR.

Results

Among 556 screened patients, 400 were enrolled and 363 completed follow-up. The mean patient age was 40 years, and 59% were men. The median recovery time was 7 (4-10, treatment group) and 9 (5-12, placebo group) days (hazard ratio, 0.73; 95% confidence interval, 0.60-0.90). The numbe

SUBMITTER: Mahmud R 

PROVIDER: S-EPMC8127799 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature